Background Background Persistent impairmentsin
Persistent impairmentsin neurocognitive function have been neurocognitive function have been described in patients with bipolar disorder described in patients with bipolar disorder whose disease is in remission.However, whose disease is in remission.However, methodological issues such as the effect of methodological issues such as the effect of residual mood symptoms and residual mood symptoms and hypercortisolaemia may confound such hypercortisolaemia may confound such studies. studies.
Aims Aims To assess neurocognitive
To assess neurocognitive functioning in prospectively verified functioning in prospectively verified euthymic patients with bipolar disorder. euthymic patients with bipolar disorder.
Method Method Sixty-three patients with
Sixty-three patients with bipolar disorder and a matched control bipolar disorder and a matched control group completed a comprehensive group completed a comprehensive neurocognitive test battery.Euthymia was neurocognitive test battery.Euthymia was confirmed in the patient group by confirmed in the patient group by prospective clinical ratings over1month prospective clinical ratings over1month prior to testing. Saliva samples were prior to testing. Saliva samples were collected to profile basal cortisol collected to profile basal cortisol secretion. secretion.
Results

Results Patients were significantly
Patients were significantly impaired across a broad range of cognitive impaired across a broad range of cognitive domains. Across the domains tested, domains. Across the domains tested, clinically significant impairment was clinically significant impairment was observed in 3% to 42% of patients. observed in 3% to 42% of patients. Deficits were not causally associated with Deficits were not causally associated with residual mood symptoms or residual mood symptoms or hypercortisolaemia. hypercortisolaemia.
Conclusions Conclusions Neurocognitive
Neurocognitive impairment persists in patients whose impairment persists in patients whose bipolar disorder is in remission.This may bipolar disorder is in remission.This may represent a trait abnormality and be a represent a trait abnormality and be a marker of underlying neurobiological marker of underlying neurobiological dysfunction. dysfunction.
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Converging evidence suggests that people Converging evidence suggests that people with bipolar disorder exhibit persistent cogwith bipolar disorder exhibit persistent cognitive impairment across a range of tasks of nitive impairment across a range of tasks of attention, memory and executive function attention, memory and executive function during remission (van Gorp during remission (van Gorp et al et al, 1998; , 1998; Ferrier Ferrier et al et al, 1999; Rubinsztein , 1999; Rubinsztein et al et al, , 2000; Clark 2000; Clark et al et al, 2002; Tavares , 2002; Tavares et al et al, , 2003; Martinez-Aran 2003; Martinez-Aran et al et al, 2004) . How-, 2004) . However, small sample sizes, the effects of resiever, small sample sizes, the effects of residual mood symptoms and different rates dual mood symptoms and different rates of biological abnormalities such as hyperof biological abnormalities such as hypercortisolaemia may confound such studies. cortisolaemia may confound such studies. Importantly, few studies have examined Importantly, few studies have examined the magnitude of impairment in a meaningthe magnitude of impairment in a meaningful way, i.e. as effect sizes or in terms of the ful way, i.e. as effect sizes or in terms of the proportion of patients with 'clinically sigproportion of patients with 'clinically significant' impairment. This study sought to nificant' impairment. This study sought to address previous limitations by testing a address previous limitations by testing a large sample of well-characterised, proslarge sample of well-characterised, prospectively verified euthymic patients with pectively verified euthymic patients with bipolar disorder on a comprehensive bipolar disorder on a comprehensive neuropsychological test battery. We preneuropsychological test battery. We predicted that patients would demon dicted that patients would demonstrate strate clear neurocognitive impairment compared clear neurocognitive impairment compared with healthy controls. with healthy controls.
METHOD METHOD Participants Participants
Sixty-three people with a DSM-IV diagSixty-three people with a DSM-IV diagnosis of bipolar affective disorder (American nosis of bipolar affective disorder (American Psychiatric Association, 1994) were rePsychiatric Association, 1994) were recruited from out-patient clinics in secondcruited from out-patient clinics in secondary and tertiary care in the north-east of ary and tertiary care in the north-east of England; 54 had bipolar type I disorder, 9 England; 54 had bipolar type I disorder, 9 had type II and 5 were rapid-cycling. Diaghad type II and 5 were rapid-cycling. Diagnoses were confirmed using the Structured noses were confirmed using the Structured Clinical Interview for DSM-IV (SCID; First Clinical Interview for DSM-IV (SCID; First et al et al, 1997) . Illness characteristics were , 1997). Illness characteristics were derived from retrospective life charts conderived from retrospective life charts constructed from patient interview and hosstructed from patient interview and hospital medical records (Leverich & Post, pital medical records (Leverich & Post, 1996) . Patients were excluded if they were 1996). Patients were excluded if they were taking corticosteroids or antihypertensive taking corticosteroids or antihypertensive medication, had any other current Axis I medication, had any other current Axis I diagnosis or had a neurological or medical diagnosis or had a neurological or medical condition. A history of substance or alcohol condition. A history of substance or alcohol misuse in the past 6 months (6 patients met misuse in the past 6 months (6 patients met DSM-IV criteria for a previous history of DSM-IV criteria for a previous history of alcohol dependence, 4 met criteria for a alcohol dependence, 4 met criteria for a previous history of substance dependence previous history of substance dependence and 1 patient met criteria for previous suband 1 patient met criteria for previous substance and alcohol dependence) or electrostance and alcohol dependence) or electroconvulsive therapy (ECT) in the past year convulsive therapy (ECT) in the past year also led to exclusion. also led to exclusion.
Euthymia was prospectively defined as Euthymia was prospectively defined as scores of 7 or below on both the Hamilton scores of 7 or below on both the Hamilton Rating Scale for Depression (HRSD; Rating Scale for Depression (HRSD; Hamilton, 1960) .00 h and 20.00 h on the day before 16.00 h and 20.00 h on the day before testing confirmed that patients were eucortesting confirmed that patients were eucortisolaemic (i.e. exhibited normal rhythm tisolaemic (i.e. exhibited normal rhythm and secretion of cortisol), as measured by and secretion of cortisol), as measured by directed disequilibrium radioimmunoassay. directed disequilibrium radioimmunoassay. With the exception of 3 patients who were With the exception of 3 patients who were taking no medication, all patients were taking no medication, all patients were stabilised on prophylactic medication at stabilised on prophylactic medication at test; 40 were receiving combination treattest; 40 were receiving combination treatment. Demographic and clinical characterment. Demographic and clinical characteristics of the sample are presented in istics of the sample are presented in Table 1 . Table 1. For the control group, 63 healthy For the control group, 63 healthy volunteers were recruited from the comvolunteers were recruited from the community by local advertisement. Controls munity by local advertisement. Controls were matched on an individual basis with were matched on an individual basis with patients for age ( patients for age (+ +5 years), gender, race, 5 years), gender, race, handedness (Briggs & Nebes, 1975) , years handedness (Briggs & Nebes, 1975) , years of education ( of education (+ +3 years), and premorbid 3 years), and premorbid IQ ( IQ (+ +5 IQ points; Nelson, 1982) . Controls 5 IQ points; Nelson, 1982) . Controls were screened for significant medical condiwere screened for significant medical conditions and were excluded if they had a tions and were excluded if they had a current or past psychiatric illness (confirmed current or past psychiatric illness (confirmed by SCID) or a family history of affective by SCID) or a family history of affective disorders in a first-degree relative, or were disorders in a first-degree relative, or were taking any medication other than the oral taking any medication other than the oral contraceptive pill. Control participants contraceptive pill. Control participants completed the same clinical ratings as completed the same clinical ratings as patients on the study day, 1 week after patients on the study day, 1 week after completing a pre-screen AMRS and BDI. completing a pre-screen AMRS and BDI.
For all participants, historic and current For all participants, historic and current substance use was assessed using DSM-IV substance use was assessed using DSM-IV criteria and a detailed inventory was decriteria and a detailed inventory was derived from the major DSM-IV substance rived from the major DSM-IV substance classifications. To exclude people with classifications. To exclude people with current alcohol misuse, participants had to current alcohol misuse, participants had to have a current alcohol intake of less than have a current alcohol intake of less than 28 units per week for men and 21 units 28 units per week for men and 21 units per week for women. The Modified Miniper week for women. The Modified MiniMental State Examination (Teng & Chui, Mental State Examination (Teng & Chui, 1987) was administered on the study day 1987) was administered on the study day to screen for dementia. The local ethics to screen for dementia. The local ethics committee approved the investigation. committee approved the investigation.
Neuropsychological measures Neuropsychological measures
Participants completed a comprehensive Participants completed a comprehensive battery of neurocognitive tests spanning battery of neurocognitive tests spanning four broad cognitive domains. To control four broad cognitive domains. To control for the possible effects of diurnal variation for the possible effects of diurnal variation on performance, cognitive testing comon performance, cognitive testing commenced at 14.00 h. Tests were administered menced at 14.00 h. Tests were administered according to standard instructions and took according to standard instructions and took about 2 h to complete. The tasks were given about 2 h to complete. The tasks were given in the same order to the whole sample. The in the same order to the whole sample. The instruments administered for each domain instruments administered for each domain were as follows: were as follows: The SOPT and CANTAB tasks were The SOPT and CANTAB tasks were presented on a 486 microcomputer fitted presented on a 486 microcomputer fitted with a high-resolution 38 cm touch-screen with a high-resolution 38 cm touch-screen monitor. Detailed descriptions of the monitor. Detailed descriptions of the CANTAB tasks are provided in Robbins CANTAB tasks are provided in Robbins et al et al (1997) and further details regarding (1997) and further details regarding the pen-and-paper measures in Lezak the pen-and-paper measures in Lezak (1995 Lezak ( ). (1995 . 
Statistical analyses Statistical analyses
Analyses were conducted using the StatistiAnalyses were conducted using the Statistical Package for the Social Sciences, version cal Package for the Social Sciences, version 9 (SPSS, 1998). Data were first examined to 9 (SPSS, 1998). Data were first examined to see whether they fulfilled the assumptions see whether they fulfilled the assumptions for parametric analyses. Variables fulfilling for parametric analyses. Variables fulfilling these assumptions were analysed by indethese assumptions were analysed by independent samples pendent samples t t-test or analysis of -test or analysis of variance (ANOVA), with group (patient variance (ANOVA), with group (patient or control) as the between-subject factor. or control) as the between-subject factor. For tests with more than one level and the For tests with more than one level and the cortisol data, an additional within-subject cortisol data, an additional within-subject factor of 'time' or 'problem level' was factor of 'time' or 'problem level' was added. Where sphericity was violated, added. Where sphericity was violated, within-subject degrees of freedom were within-subject degrees of freedom were adjusted using Greenhouse-Geisser or adjusted using Greenhouse-Geisser or Huynh-Feldt corrections as appropriate. Huynh-Feldt corrections as appropriate. Adjusted Adjusted P P values are reported, although values are reported, although the original degrees of freedom are also the original degrees of freedom are also reported for clarity. Data not fulfilling the reported for clarity. Data not fulfilling the assumptions of parametric analyses were assumptions of parametric analyses were either subjected to an appropriate transeither subjected to an appropriate transformation or analysed non-parametrically formation or analysed non-parametrically (Howell, 1997) . (Howell, 1997) .
To calculate clinically significant perTo calculate clinically significant performance impairments, the proportion of formance impairments, the proportion of patients scoring on or below the fifth perpatients scoring on or below the fifth percentile was determined (i.e. centile was determined (i.e. 7
71.64 stand-1.64 standard deviations from the mean of the control ard deviations from the mean of the control sample). Estimates of effect size were calcusample). Estimates of effect size were calculated for untransformed data using the lated for untransformed data using the formula ( formula (m m patients patients 7 7m m controls controls )/ )/s s pooled pooled (Howell, (Howell, 1999) ; the first part of this equation was 1999); the first part of this equation was reversed for tasks where a high score reversed for tasks where a high score indicates poorer performance (i.e. indicates poorer performance (i.e. m m controls controls 7 7 m m patients patients ) to standardise the scoring schemes ) to standardise the scoring schemes across tasks. All reported across tasks. All reported P P values are values are two-tailed. To examine the impact of illness two-tailed. To examine the impact of illness severity on neurocognitive performance, severity on neurocognitive performance, correlations between illness characteristics correlations between illness characteristics and neurocognitive test variables were and neurocognitive test variables were calculated using Spearman's method. calculated using Spearman's method.
RESULTS RESULTS
Demographic and mood data Demographic and mood data
There was no significant between-group There was no significant between-group difference across the demographic varidifference across the demographic variables. On the clinical rating scales patients ables. On the clinical rating scales patients exhibited few symptoms during the euthyexhibited few symptoms during the euthymia verification period, although their mia verification period, although their scores were still significantly higher than scores were still significantly higher than the controls on most of the measures the controls on most of the measures completed by both groups (Table 1) . completed by both groups (Table 1) .
Basal salivary cortisol measures Basal salivary cortisol measures
Basal salivary cortisol samples were Basal salivary cortisol samples were collected from 54 people in the control collected from 54 people in the control group and 56 patients. Comparison group and 56 patients. Comparison between patients and controls illustrated between patients and controls illustrated the expected main effect of time the expected main effect of time ( (F F (3,324) (3,324) ¼99.18, 99.18, P P5 50.0001) but no main 0.0001) but no main effect of group ( effect of group (F F (1,108) (1,108) ¼1.13, 1.13, P P¼0.29) or 0.29) or group group6 6time interaction ( time interaction (F F (3,324) (3,324) ¼0.54, 0.54, P P¼0.56). Overall cortisol output did not 0.56). Overall cortisol output did not differ between the groups ( differ between the groups (P P4 40.2). 0.2).
Cognitive measures Cognitive measures
Group mean performance and statistical Group mean performance and statistical comparisons for all cognitive measures are comparisons for all cognitive measures are summarised in Table 2 . In tests comprising summarised in Table 2 . In tests comprising a delay or difficulty level variable, only a delay or difficulty level variable, only main effects and interactions involving main effects and interactions involving group variables are reported below: main group variables are reported below: main effects of delay or difficulty level were sigeffects of delay or difficulty level were significant in all cases (excluding Vigil latency nificant in all cases (excluding Vigil latency and omissions) but are not presented here. and omissions) but are not presented here. In Table 3 , outcome measures from each In Table 3 , outcome measures from each test are sorted by effect size, with Cohen's test are sorted by effect size, with Cohen's conventions used to indicate small, medium conventions used to indicate small, medium and large effects (Cohen, 1988) . The proand large effects (Cohen, 1988) . The proportion of patients scoring at or below the portion of patients scoring at or below the fifth percentile of the control group is also fifth percentile of the control group is also presented. presented.
Psychomotor performance Psychomotor performance
Patients' response times were significantly Patients' response times were significantly slower than the control group on the Vigil slower than the control group on the Vigil task. There was no group task. There was no group6 6time interaction time interaction ( (F F (3,369) (3,369) ¼0.438, 0.438, P P¼0.67), suggesting that 0.67), suggesting that patients were impaired throughout the task. patients were impaired throughout the task. Patients were also significantly slower than Patients were also significantly slower than controls to complete part A of the Trail controls to complete part A of the Trail Making Test and produced significantly Making Test and produced significantly fewer correct responses on the Digit fewer correct responses on the Digit Symbol Substitution Test. Symbol Substitution Test.
Attention and executive function Attention and executive function
In contrast to the performance deficit on In contrast to the performance deficit on part A of the Trail Making Test, patients part A of the Trail Making Test, patients and controls did not significantly differ on and controls did not significantly differ on part B of this task. On the Vigil task, part B of this task. On the Vigil task, patients made significantly more errors of patients made significantly more errors of omission than controls; however, commisomission than controls; however, commission errors did not differ between groups. sion errors did not differ between groups. Analysis of omission errors across time Analysis of omission errors across time revealed that patients were impaired revealed that patients were impaired throughout this task, indicated by the throughout this task, indicated by the absence of a significant group absence of a significant group6 6time intertime interaction ( action (F F (3,369) (3,369) ¼0.833, 0.833, P P¼0.471). Patients' 0.471). Patients' performance was also significantly poorer performance was also significantly poorer than that of the control group on the Stroop than that of the control group on the Stroop task and their response accuracy on the task and their response accuracy on the Tower of London task was impaired. On Tower of London task was impaired. On the latter task's latency measures, patients' the latter task's latency measures, patients' motor initiation and motor execution times motor initiation and motor execution times were significantly greater than those of the were significantly greater than those of the controls, as were their overall initial and controls, as were their overall initial and subsequent thinking times. However, when subsequent thinking times. However, when 3 4 3 4 Where there is more than one level of difficulty for a particular task, the mean score collapsed across levels or stages is reported. 1. Where there is more than one level of difficulty for a particular task, the mean score collapsed across levels or stages is reported. 2. Note that this task taps the resources of both the visuospatial sketchpad and the central executive, although results from this task are reported only once in the table for the sake 2. Note that this task taps the resources of both the visuospatial sketchpad and the central executive, although results from this task are reported only once in the table for the sake of parsimony. On the strategy index, a high score represents a lower use of strategy. of parsimony. On the strategy index, a high score represents a lower use of strategy. 3. As the standard delayed recall index (trial A7) is critically dependent on the number of words initially encoded (i.e. is confounded by initial learning), the percentage of words 3. As the standard delayed recall index (trial A7) is critically dependent on the number of words initially encoded (i.e. is confounded by initial learning), the percentage of words retained between trials A5 and A7 was used to provide a purer index of retention retained between trials A5 and A7 was used to provide a purer index of retention per se per se. .
3 6 3 6 (Cohen, 1988) . 0.8) effect sizes (Cohen, 1988) .
the motor times were subtracted from the the motor times were subtracted from the thinking times to provide indices of planthinking times to provide indices of planning times ning times per se per se, patients' initial and sub-, patients' initial and subsequent response times did not differ sequent response times did not differ significantly from controls. No group significantly from controls. No group6 6level level interaction was present across any Tower interaction was present across any Tower of London index ( of London index (P P5 50.169). On the Con-0.169). On the Controlled Oral Word Association Test, trolled Oral Word Association Test, patients generated significantly fewer patients generated significantly fewer correct responses than controls, but made correct responses than controls, but made no more perseverative responses, and they no more perseverative responses, and they recalled significantly fewer digits on the recalled significantly fewer digits on the Digits Backward test. On the SOPT, there Digits Backward test. On the SOPT, there was a significant main effect of group, was a significant main effect of group, as patients made significantly more as patients made significantly more errors than controls, but no group errors than controls, but no group6 6set-size set-size interaction ( interaction (F F (3,309) (3,309) ¼0.632, 0.632, P P¼0.586). For 0.586). For Spatial Working Memory between-search Spatial Working Memory between-search errors there was a significant main effect errors there was a significant main effect of group, with patients making significantly of group, with patients making significantly more errors than controls, but again no more errors than controls, but again no group group6 6level interaction ( level interaction (F F (2,248) (2,248) ¼0.931, 0.931, P P¼0.387); however, on this test's strategy 0.387); however, on this test's strategy index, patients' scores were no different index, patients' scores were no different from controls. from controls.
Immediate memory Immediate memory
Unlike their performance on the Digits Unlike their performance on the Digits Forward task, patients' CANTAB Spatial Forward task, patients' CANTAB Spatial Span scores were significantly below those Span scores were significantly below those of the controls. of the controls.
Declarative memory Declarative memory
Patients' performance was no different Patients' performance was no different from that of controls on the CANTAB from that of controls on the CANTAB Pattern Recognition Memory task, but they Pattern Recognition Memory task, but they showed significant impairment on the showed significant impairment on the Spatial Recognition Memory task. On the Spatial Recognition Memory task. On the CANTAB Matching to Sample tasks there CANTAB Matching to Sample tasks there was no between-group difference when was no between-group difference when the stimuli were presented simultaneously. the stimuli were presented simultaneously. On the delayed trials, however, patients' On the delayed trials, however, patients' performance was significantly poorer than performance was significantly poorer than controls'. The absence of a group controls'. The absence of a group6 6delay delay interaction ( interaction (F F (2,240) (2,240) ¼0.867, 0.867, P P¼0.422) sug-0.422) suggests that the deficit is not delay-dependent. gests that the deficit is not delay-dependent. On the Paired Associates Learning test On the Paired Associates Learning test patients required significantly more trials patients required significantly more trials than controls to complete the task. Patients than controls to complete the task. Patients also completed fewer sets successfully and also completed fewer sets successfully and located fewer patterns correctly after a located fewer patterns correctly after a single presentation. single presentation.
Patients' verbal learning was signifiPatients' verbal learning was significantly poorer than that of controls (RAVLT cantly poorer than that of controls (RAVLT trials A1-A5). Patients' performance was trials A1-A5). Patients' performance was also impaired on the RAVLT distracter also impaired on the RAVLT distracter word list recall trial (list B), postword list recall trial (list B), postinterference recall (trial A6), number of interference recall (trial A6), number of targets correctly identified on the targets correctly identified on the recognition trial, and on the standard index recognition trial, and on the standard index of delayed recall (A7). However, when the of delayed recall (A7). However, when the delayed recall index was modified to condelayed recall index was modified to control for the confounding effects of patients' trol for the confounding effects of patients' reduced encoding (see footnote 3 in Table  reduced encoding (see footnote 3 in Table  2 ), patients' performance did not differ 2), patients' performance did not differ from controls, suggesting that retention in from controls, suggesting that retention in long-term memory long-term memory per se per se is intact. Also, pais intact. Also, patients committed no more errors of comtients committed no more errors of commission than did controls on the RAVLT mission than did controls on the RAVLT recognition trial and their immediate span recognition trial and their immediate span (trial A1) was intact. (trial A1) was intact.
Post hoc Post hoc multivariate analysis by multivariate analysis by neurocognitive domain neurocognitive domain
Studies of neurocognitive function are freStudies of neurocognitive function are frequently at risk of type I error because of quently at risk of type I error because of the number of comparisons conducted in the number of comparisons conducted in the analysis. Multiple comparisons are a the analysis. Multiple comparisons are a product of the need to use several tasks to product of the need to use several tasks to profile the range of different neurocognitive profile the range of different neurocognitive processes. One approach that has been processes. One approach that has been suggested to overcome this problem is to suggested to overcome this problem is to group together tests and outcome measures group together tests and outcome measures that have some degree of theoretical overthat have some degree of theoretical overlap (Stevens, 2002) , i.e. apply to a specific lap (Stevens, 2002) , i.e. apply to a specific neurocognitive domain. This method was neurocognitive domain. This method was therefore adopted and it confirmed that a therefore adopted and it confirmed that a significant multivariate statistic (Hotelsignificant multivariate statistic (Hotelling's trace) was present in each of the four ling's trace) was present in each of the four 3 7 3 7 
Effects of residual mood symptoms Effects of residual mood symptoms
Residual mood symptoms have been found Residual mood symptoms have been found to impair cognition in affective disorders to impair cognition in affective disorders (Ferrier (Ferrier et al et al, 1999; Clark , 1999; Clark et al et al, 2002) . As , 2002). As patients' mood scores on many of the clinpatients' mood scores on many of the clinical rating scales used in this study were ical rating scales used in this study were significantly higher than those of controls, significantly higher than those of controls, a series of analyses were performed to rule a series of analyses were performed to rule out this potential confound on the observed out this potential confound on the observed deficits. Correlations between the clinical deficits. Correlations between the clinical rating scales and neurocognitive tests illusrating scales and neurocognitive tests illustrating between-group differences were first trating between-group differences were first calculated, to establish which deficits might calculated, to establish which deficits might have been influenced by mood. Partial have been influenced by mood. Partial correlations were subsequently performed correlations were subsequently performed on any cognitive index that significantly on any cognitive index that significantly correlated with the mood ratings, to examcorrelated with the mood ratings, to examine whether the previously observed ine whether the previously observed between-group differences on these indices between-group differences on these indices remained when the effect of mood on remained when the effect of mood on performance was partialled out. These performance was partialled out. These analyses illustrated that 11 cognitive indices analyses illustrated that 11 cognitive indices correlated significantly with the rating correlated significantly with the rating scales. However, when the effects of mood scales. However, when the effects of mood on these variables were controlled, all on these variables were controlled, all between-group effects remained significant between-group effects remained significant (apart from subsequent thinking time on (apart from subsequent thinking time on the Tower of London task) when the BDI the Tower of London task) when the BDI scores on the day of test and at week 4 were scores on the day of test and at week 4 were partialled out ( partialled out (P P¼0.066). 0.066).
Relationship between illness Relationship between illness characteristics and neurocognitive characteristics and neurocognitive function function
To restrict the number of correlations comTo restrict the number of correlations computed between the illness characteristics puted between the illness characteristics and the neurocognitive test variables, only and the neurocognitive test variables, only those indices illustrating between-group those indices illustrating between-group differences were examined. In addition, differences were examined. In addition, only the most representative variable from only the most representative variable from each of the cognitive tasks was included. each of the cognitive tasks was included. The results of these analyses are presented The results of these analyses are presented in Table 4 . in Table 4 .
Relationship between basal cortisol Relationship between basal cortisol levels and neurocognitive function levels and neurocognitive function Correlations between cortisol area under Correlations between cortisol area under the curve and neurocognitive indices were the curve and neurocognitive indices were also examined for patients and controls also examined for patients and controls separately. In patients, the only significant separately. In patients, the only significant correlations observed were for the 
DISCUSSION DISCUSSION
Our study demonstrates significant neuroOur study demonstrates significant neurocognitive impairment in a prospectively cognitive impairment in a prospectively verified sample of euthymic patients with verified sample of euthymic patients with bipolar disorder, compared with a wellbipolar disorder, compared with a wellmatched control group. Patients were matched control group. Patients were impaired across a range of cognitive impaired across a range of cognitive domains, including attention and executive domains, including attention and executive function, immediate (spatial) memory and function, immediate (spatial) memory and verbal and visuospatial declarative memverbal and visuospatial declarative memory. Significant psychomotor retardation ory. Significant psychomotor retardation was also evident. These impairments were was also evident. These impairments were not attributable to hypercortisolism, not attributable to hypercortisolism, because basal salivary cortisol profiling because basal salivary cortisol profiling revealed no difference between patients revealed no difference between patients and controls. Also, dysfunction was still and controls. Also, dysfunction was still evident after controlling for the effects of evident after controlling for the effects of residual mood symptoms residual mood symptoms post hoc post hoc using a using a partial correlational analysis. partial correlational analysis.
Previous neuropsychological Previous neuropsychological findings in bipolar disorder findings in bipolar disorder
Our findings are consistent with a growing Our findings are consistent with a growing body of evidence that people with bipolar body of evidence that people with bipolar disorder experience a range of cognitive disorder experience a range of cognitive deficits during disease remission (van Gorp deficits during disease remission (van Gorp et al et al, 1998; Ferrier , 1998; Ferrier et al et al, 1999; Rubinsztein , 1999; Rubinsztein et al et al, 2000; Clark , 2000; Clark et al et al, 2002; Martinez-, 2002; MartinezAran Aran et al et al, 2004) . Many studies have used , 2004). Many studies have used structured interviews and standardised structured interviews and standardised rating scales to demonstrate the euthymic rating scales to demonstrate the euthymic status of patients, but generally their status of patients, but generally their sample sizes were smaller than ours and sample sizes were smaller than ours and prospective follow-up or cortisol measureprospective follow-up or cortisol measurements were not recorded. The majority of ments were not recorded. The majority of studies to date have typically defined studies to date have typically defined patients as impaired on the basis of a patients as impaired on the basis of a between-group difference (from controls) between-group difference (from controls) on an arbitrarily selected significance level. on an arbitrarily selected significance level. However, although a result might be statisHowever, although a result might be statistically significant, this says nothing about tically significant, this says nothing about the size of the effect, nor does it guarantee the size of the effect, nor does it guarantee that it is clinically important. Few studies that it is clinically important. Few studies have provided data on the number of have provided data on the number of patients falling within the clinically patients falling within the clinically impaired range on particular tasks, despite impaired range on particular tasks, despite normative data being readily available to normative data being readily available to do so (but see Rubinsztein do so (but see Rubinsztein et al et al, 2000) . , 2000). et al, 1959; Bratfos & Haug, , 1959; Bratfos & Haug, 1968; Dhingra & Rabins, 1991; Martinez-1968; Dhingra & Rabins, 1991; MartinezAran Aran et al et al, 2000) . Our results demonstrate , 2000). Our results demonstrate that the proportion affected is extremely that the proportion affected is extremely variable and is dependent upon the particuvariable and is dependent upon the particular task employed. For example, for tasks lar task employed. For example, for tasks within a medium to large effect size, on within a medium to large effect size, on average 25% of patients scored at or below average 25% of patients scored at or below the fifth percentile, although on some tasks the fifth percentile, although on some tasks (such as the Digit Symbol Substitution Test) (such as the Digit Symbol Substitution Test) the proportion was over 33%. This figure the proportion was over 33%. This figure averaged almost 15% for tasks falling in averaged almost 15% for tasks falling in the small to medium effect size range. Even the small to medium effect size range. Even for tasks with little or no between-group for tasks with little or no between-group difference (i.e. difference (i.e. d d5 50.2), clinically significant 0.2), clinically significant deficits were still evident in some individdeficits were still evident in some individuals. This is of particular clinical importuals. This is of particular clinical importance because these deficits were observed ance because these deficits were observed in a cohort of patients who had been euthyin a cohort of patients who had been euthymic for an average of 27.3 months (median mic for an average of 27.3 months (median 14 months), suggesting that neurocognitive 14 months), suggesting that neurocognitive impairment persists long beyond the point impairment persists long beyond the point of symptomatic recovery. The enduring of symptomatic recovery. The enduring nature of this impairment is also highnature of this impairment is also highlighted by the absence of association lighted by the absence of association between the length of time patients had between the length of time patients had been in remission and the extent of neurobeen in remission and the extent of neurocognitive impairment. cognitive impairment.
Factors affecting neurocognitive Factors affecting neurocognitive impairment in bipolar disorder impairment in bipolar disorder
All but three of the patients in this study All but three of the patients in this study were receiving medication at the time of were receiving medication at the time of testing, therefore the effects of psychotropic testing, therefore the effects of psychotropic drugs on neurocognitive functioning cannot drugs on neurocognitive functioning cannot be excluded. Lithium use, for example, has be excluded. Lithium use, for example, has been shown to have subtle but definite been shown to have subtle but definite effects on several domains, including effects on several domains, including psychomotor speed and possibly verbal psychomotor speed and possibly verbal memory. Similarly, antidepressants have memory. Similarly, antidepressants have been shown to have cognitive effects, partibeen shown to have cognitive effects, particularly those with anticholinergic propercularly those with anticholinergic properties (Amado-Boccara ties (Amado-Boccara et al et al, 1995) . , 1995). However, in their review, Bearden However, in their review, Bearden et al et al (2001) suggest that the cognitive impair- (2001) suggest that the cognitive impairments in bipolar illness are unlikely to be ments in bipolar illness are unlikely to be a primary effect of medication. In a coma primary effect of medication. In a comparison study of euthymic patients with biparison study of euthymic patients with bipolar disorder and controls, neurocognitive polar disorder and controls, neurocognitive impairment was observed not only in paimpairment was observed not only in patients receiving mood-stabiliser monothertients receiving mood-stabiliser monotherapy but also in those who were drug-free apy but also in those who were drug-free (Goswami (Goswami et al et al, 2002) . None the less, many , 2002). None the less, many patients with this disorder take several psypatients with this disorder take several psychotropic medications at varying doses, and chotropic medications at varying doses, and it is unknown what the effects of combined it is unknown what the effects of combined therapy might be, particularly over time. Sitherapy might be, particularly over time. Similarly, although ECT may affect neuromilarly, although ECT may affect neurocognitive function in some patients, only cognitive function in some patients, only half the half the patients in our study had ever repatients in our study had ever received ECT and a negative effect of the numceived ECT and a negative effect of the number of previous treatments on performance ber of previous treatments on performance was observed on a small number of tests. was observed on a small number of tests.
Different rates of neurobiological Different rates of neurobiological abnormalities among patients with bipolar abnormalities among patients with bipolar disorder may also affect the pattern and disorder may also affect the pattern and magnitude of neurocognitive impairment. magnitude of neurocognitive impairment. Elevated cortisol levels have been shown to Elevated cortisol levels have been shown to impair specific domains of neurocognitive impair specific domains of neurocognitive functioning, both in studies in which synfunctioning, both in studies in which synthetic glucocorticoids were administered thetic glucocorticoids were administered exogenously and in patient groups with exogenously and in patient groups with chronically elevated endogenous cortisol chronically elevated endogenous cortisol levels (e.g. Cushing's disease). As hypolevels (e.g. Cushing's disease). As hypothalamic-pituitary-adrenal axis dysfuncthalamic-pituitary-adrenal axis dysfunction in bipolar disorder may also persist in tion in bipolar disorder may also persist in a proportion of euthymic patients (Watson a proportion of euthymic patients (Watson et al et al, 2004) , in our study saliva samples were , 2004), in our study saliva samples were collected on the day prior to testing to procollected on the day prior to testing to provide a simple, non-invasive assessment of vide a simple, non-invasive assessment of basal cortisol secretion. No difference bebasal cortisol secretion. No difference between patients and controls was observed, tween patients and controls was observed, potentially excluding this confound. Howpotentially excluding this confound. However, basal cortisol profiling is relatively ever, basal cortisol profiling is relatively insensitive compared with 'activating' chalinsensitive compared with 'activating' challenges such as the dexamethasone/corticolenges such as the dexamethasone/corticotrophin releasing hormone test, which trophin releasing hormone test, which might be more informative in future studies might be more informative in future studies (Watson (Watson et al et al, 2004) . , 2004). Several studies have reported that resiSeveral studies have reported that residual mood symptoms may affect the degree dual mood symptoms may affect the degree of neurocognitive dysfunction observed in of neurocognitive dysfunction observed in euthymic patients with bipolar disorder euthymic patients with bipolar disorder (Ferrier (Ferrier et al et al, 1999; Clark , 1999; Clark et al et al, 2002) . When , 2002) . When residual mood symptoms were statistically residual mood symptoms were statistically controlled in our study, all between-group controlled in our study, all between-group differences remained with the exception of differences remained with the exception of one. As we recruited a larger cohort than one. As we recruited a larger cohort than in the earlier studies, residual symptoms in the earlier studies, residual symptoms may exert only subtle effects on performay exert only subtle effects on performance and are less problematic when the mance and are less problematic when the statistical power of the study is increased. statistical power of the study is increased. The observed impairment is therefore The observed impairment is therefore unlikely to be an epiphenomenon of mood. unlikely to be an epiphenomenon of mood.
Clinico-cognitive correlations: Clinico-cognitive correlations: disease process or trait deficit? disease process or trait deficit?
Several studies have reported that patients Several studies have reported that patients with a more severe course of prior illness with a more severe course of prior illness and greater number of episodes suffer and greater number of episodes suffer greater neurocognitive decline (Kessing, greater neurocognitive decline (Kessing, 1998; van Gorp 1998; van Gorp et al et al, 1998; Denicoff , 1998; Denicoff et et al al, 1999) . In our study, examination of , 1999). In our study, examination of the correlation between illness history charthe correlation between illness history characteristics and neurocognitive functioning acteristics and neurocognitive functioning revealed an effect of several factors, partirevealed an effect of several factors, particularly lifetime duration of illness and cularly lifetime duration of illness and number of hospitalisations, consistent with number of hospitalisations, consistent with several previous reports (Tham several previous reports (Tham et al et al, 1997; , 1997; Denicoff Denicoff et al et al, 1999; Rubinsztein , 1999; Rubinsztein et al et al, , 2000) . Such associations have typically 2000). Such associations have typically been interpreted as indicating a progressive been interpreted as indicating a progressive disease process. However, the direction of disease process. However, the direction of causality cannot be determined from correcausality cannot be determined from correlational analyses. These results may equally lational analyses. These results may equally indicate that patients with neurocognitive indicate that patients with neurocognitive impairments are more vulnerable to develimpairments are more vulnerable to developing a severe and recurrent bipolar disoroping a severe and recurrent bipolar disorder. Preliminary evidence indicates subtle der. Preliminary evidence indicates subtle neurocognitive impairments in 'high-risk' neurocognitive impairments in 'high-risk' groups, i.e. first-degree relatives of patients groups, i.e. first-degree relatives of patients with bipolar disorder (Keri with bipolar disorder (Keri et al et al, 2001; , 2001; Chowdhury Chowdhury et al et al, 2002; Sobczak , 2002; Sobczak et al et al, , 2002) . Therefore, although some deficits 2002). Therefore, although some deficits might be the result of disease progression, might be the result of disease progression, evidence that impairments occur both in evidence that impairments occur both in euthymic patients with bipolar disorder euthymic patients with bipolar disorder and their healthy first-degree relatives may and their healthy first-degree relatives may represent an endophenotypic marker of represent an endophenotypic marker of genetic vulnerability. genetic vulnerability. Goswami,U., Gulrajani, C., Moore, P. B., Goswami, U., Gulrajani, C., Moore, P. B., et al et al (2002) 
Neurocognitive decline in bipolar mood disorder: role Neurocognitive decline in bipolar mood disorder: role
